Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
September 30 2015 - 8:00PM
Business Wire
Amoy Diagnostics Co. Ltd. (ADx) and Illumina,
Inc. (NASDAQ: ILMN) today announced a
strategic collaboration to accelerate the adoption
of precision medicine and targeted therapies in
China. Under the collaboration, Amoy will develop
and commercialize a series of oncology-related tests based
on Illumina’s next-generation sequencing (NGS) platforms,
including the recently released research use only TruSight Tumor 15
as transferred from Illumina to Amoy. The collaboration reflects
the commitment of both companies to provide integrated solutions to
meet clinical needs in China.
“Our genetic tests for detection of EGFR, KRAS, NRAS and BRAF
mutations, and ALK and ROS-1 fusions, have led the way for
precision medicine adoption in clinical oncology across China.
However, as the number of clinically actionable genetic variants in
cancer increases, NGS technology is crucial in order for companion
diagnostics to keep pace. Illumina is the world-leader in NGS and a
natural partner for our company. We intend to combine Amoy’s
expertise in molecular diagnostics with Illumina’s superior NGS
technology to better serve Chinese cancer patients,” said Dr. Limou
Zheng, CEO and President of Amoy Diagnostics.
“We are excited to announce this strategic collaboration with
Amoy, which will increase access to our advanced NGS technology in
the clinical oncology market in China. Genetic changes are a major
cause of cancer development, and the number of clinically
actionable genomic variants is growing rapidly. NGS technology,
with its ability to generate and analyze large-scale data and its
high sensitivity in detecting rare mutations, has shown great value
and potential for oncology,” said Dr. Rick Klausner, Senior Vice
President and Chief Medical Officer of Illumina. “Working with
market leaders such as Amoy is central to Illumina’s strategy to
advance personalized cancer diagnostics globally.”
About Amoy Diagnostics
Amoy Diagnostics Co., Ltd. (AmoyDx) is a leading biotech
company which pioneered the development and commercialization of
cancer diagnostics in China. It is the largest provider of
molecular diagnostics products for personalized healthcare in
China, as well as a service center for oncology biomarker analysis.
AmoyDx has a market-leading portfolio of molecular tests and is the
therapy diagnostics partner for several major multinational
pharmaceutical companies offering precision therapies for
cancer.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in Illumina’s filings with the Securities
and Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150930006647/en/
Amoy DiagnosticsDr. Jiemin Luo, +86
5926806830Luojm@amoydx.comorIllumina, Inc.Investors:Rebecca
Chambers, 858-255-5243rchambers@illumina.comorMedia:Jennifer
Temple, 858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024